earnings
confidence high
sentiment neutral
materiality 0.70
Outlook Therapeutics reports first LYTENAVA sales, $20.2M net loss for Q3 FY2025
Outlook Therapeutics, Inc.
2025-Q3 EPS
reported -$1.60
vs consensus -$0.26
▼ miss
(-519.2%)
- First commercial sales of LYTENAVA (bevacizumab gamma) in Germany and UK; $1.5M revenue recognized.
- Net loss of $20.2M ($0.55 per share), compared to net loss of $0.89 per share in prior-year quarter.
- Adjusted net loss of $15.8M ($0.44 per share), excluding $2.3M change in promissory notes and $2.0M warrant liability.
- Cash and cash equivalents of $8.9M as of June 30, 2025.
- FDA PDUFA goal date for ONS-5010 (bevacizumab-vikg) set for August 27, 2025.
item 2.02item 9.01